Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies
- 263 Downloads
Parkinson’s, Alzheimer’s and Huntington’s diseases are chronic neurodegenerative disorders of a progressive nature which lead to a considerable deterioration of the quality of life. Their pathomechanisms display some common features, including an imbalance of the tryptophan metabolism. Alterations in the concentrations of neuroactive kynurenines can be accompanied by devastating excitotoxic injuries and metabolic disturbances. From therapeutic considerations, possibilities that come into account include increasing the neuroprotective effect of kynurenic acid, or decreasing the levels of neurotoxic 3-hydroxy-l-kynurenine and quinolinic acid. The experimental data indicate that neuroprotection can be achieved by both alternatives, suggesting opportunities for further drug development in this field.
KeywordsKynurenines Kynurenic acid Kynurenine aminotransferase Parkinson’s disease Alzheimer’s disease Huntington’s disease
This work was supported by grants RET-NORT 08/2004 and ETT 215/2006.
- Henneberry RC (1997) Excitotoxicity as a consequence of impairment of energy metabolism: the energy-linked excitotoxic hypothesis. In: Beal MF, Howell N, Bodis-Wollner I (eds) Mitochondria & free radicals in neurodegenerative diseases. Wiley, New York, pp 111–143Google Scholar
- Knyihár-Csillik E, Csillik B, Pákáski M, Krisztin-Péva B, Dobó E, Okuno E, Vécsei L (2004) Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience 126:899–914CrossRefPubMedGoogle Scholar
- Leeson PD, Baker R, Carling RW, Curtis NR, Moore KW, Williams BJ, Foster AC, Donald AE, Kemp JA, Marshall GR (1991) Kynurenic acid derivatives–structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the NMDA receptor. J Med Chem 34:1243–1252CrossRefPubMedGoogle Scholar
- Merino M, Vizuete ML, Cano J, Machado A (1999) The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+. J Neurochem 73:750–757CrossRefPubMedGoogle Scholar
- Reichmann H, Riederer P (1989) Biochemical analyses of respiratory chain enzymes in different brain regions of patients with Parkinson’s disease. BMFT Symposium “Morbus Parkinson und andere Basalganglienerkrankungen”, Bad Kissingen, p 44 (abstract)Google Scholar
- Ułas J, Weihmuller FB, Brunner LC, Marshall JF, Cotman CW (1994) Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson’s disease, Alzheimer’s disease, and mixed Parkinson’s disease/Alzheimer’s disease patients: an autoradiographic study. J Neurosci 14:6317–6324PubMedGoogle Scholar
- Vécsei L (ed) (2005) Kynurenines in the brain. From experiments to clinics. Nova, New YorkGoogle Scholar
- Wolf H (1974) Studies on tryptophan metabolism in man: The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest 136(Suppl):1–186Google Scholar